Delivering a value proposition for potential investment support.

At QV Bioelectronics we are  developing innovative electrotherapy devices for the treatment of certain types of brain tumours. Compared to other diseases, the incidence of brain tumours is rare, however, the social and economic impact on society is disproportionately significant.  A 2018 parliamentary report estimated the UK economic costs of brain tumours to be £578 million each year, the third highest of all cancers despite the small numbers of patients with these diseases.

M.A.R.S Ltd has supported us to understand the nature of Glioblastoma multiforme (GBM)  the most common type of malignant brain tumour, with over 2,200 cases diagnosed each year in England and build our  value proposition to  demonstrate the full potential of our innovation to  payers and  secure access to  funding to support our on-going research and development.

Christopher Bullock PhD
CEO & Co-Founder